Outlook Therapeutics has re-submitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) ...
The FDA granted priority review to TLX250-CDx for clear cell renal cell carcinoma imaging, with a PDUFA date of August 27, ...
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...
Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ...
The FDA granted RMAT designation to nogapendekin alfa and CAR-NK for reversing lymphopenia in patients with cancer, with ...
Legit on MSN2h
Lady Schooling in Canada Shares Messages She Received from Man in His 40s Whom She RejectedAn international student has displayed the messages a man in his 40s sent her on WhatsApp because she rejected him. The ...
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...
Organogenesis ( ORGO -5.54%) Q4 2024 Earnings Call Feb 27, 2025, 5:00 p.m. ET ...
Q2 2025 Earnings Conference Call February 26, 2025 5:00 PM ETCompany ParticipantsSilviu Itescu - Chief Executive ...
The Intellectual Property Office of the Philippines (IPOPHL) said it expects a continued reduction in the resolution time of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback